James Caudell
@JJCaudell
Vice-Chair Clinical Research Section Chief, Head&Neck Rad Onc Moffitt Cancer Center @MoffittNews Specializes in treating #headandneckcancer
Strong work @ninaobertopp & @MoffittNews Pilon-Thomas lab on how 8 Gy x 1 may open options for RT-cellular therapy integration! @MoffittRadOnc @RRS_RadRes @QuadShotNews Local Single-Dose Radiation Improves Adoptive Cell Therapy With Tumor-... sciencedirect.com/science/articl…
🆕article in press: Re-examining post-operative chemoradiotherapy in head and neck cancer: An updated long-term combined analysis of RTOG 9501/EORTC 22931 @sueyom @allenhomd doi.org/10.1016/j.anno…
Recently published: Plasma Cell-Free #HPV DNA and Oral Gargle HPV DNA in Patients with HPV-related #OropharyngealCancer Treated with #Radiotherapy, by Michelle Echevarria et al. doi.org/10.1158/2767-9… @rprobinpark @JJCaudell @AmelioLab @MoffittNews #OpenAccess
🎉 We’re excited to announce that the first patient has been randomised in the PROLoNG study! 👉eortc.org/research_field… #CancerResearch #ClinicalTrials #Oncology #HeadandNeckCancer #EORTCheadandneck
Wondering why 10% of standard of care arm in keynote 689 are listed as "not treated", as compared to 1% in experimental arm.
Rising PGY-5s and anyone interested, we have a 5th HN rad onc position @MoffittNews. If interested in joining a busy team, including me, Dr. M Echevarria, @BeekeepRadOnc, and @RadOncDoc_Niema, reach out and can chat about the position.
#ClinicalTrial EA3211, led by @DavidSherMD of @utswcancer, aims to improve results for patients with #HeadAndNeckCancer that has spread to a limited number of places. Learn more: bit.ly/ea3211-study
Results from our Ph II multi-institutional study now out in @IJROBP redjournal.org/article/S0360-… Overall & objective responses noted in PD-L1 neg metastatic cervical ca with use of SBRT and atezo. Collaboration between @MoffittRadOnc @MoffittGYNONC @OhioStateRadOnc 🤝 @OncoAlert
Can PD-L1 negative cervical cancer respond to immunotherapy? At #ASCO25, Kamran Ahmed, MD, (@KAhmedMD) presents phase II results of SBRT + atezolizumab in metastatic cervical cancer, showing responses even in PD-L1 negative tumors. Read more: bit.ly/3HyjnOZ…
Critical question for C-POST. Without an OS benefit (and no real space between the curves currently), should cemiplimab be reserved for salvage?
Forest plot was pretty boring… pretty-much everyone benefitted, including CPS < 1%. Quality-of-life was the same in both arms, but patients presumably didn’t answer at recurrence. And the impact of recurrence is critical, because there was no difference in OS. Nada:
Nutrition in head and neck cancer care: a roadmap and call for research authors.elsevier.com/c/1lAZA5EllgTR…
🎙️ In honor of #HeadandNeckCancerAwarenessMonth, we’re spotlighting a new podcast episode of On Target: Logistics of Radiation Therapy in the Treatment of Head & Neck Cancers. 🎧 Listen now: astro.org/podcasts @RadOncDoc_Niema @EdinaWangMD @ASTRO_org @spohnc_1 @hncalliance
I’ve always been a fan of @PeterAttiaMD . The fact that he dedicated a podcast to low dose radiation (LDRT) for inflammatory conditions like Osteoarthritis, Plantar Fasciitis, Tendonitis and burisits is a significant milestone for our patients and specialty. LDRT is now…
Joining Forces to Advance Reirradiation: Establishing the Reirradiation Collaborative Group redjournal.org/article/S0360-…
Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients dlvr.it/TJZrTP